Cita APA (7a ed.)
Gourzoulidis, G., Chotzagiannoglou, V., Angelopoulou, A., Solakidou, E., & Tzanetakos, C. (2026, August). Cost-effectiveness analysis of liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece. Expert Review of Pharmacoeconomics & Outcomes Research, 1-10.
Cita Chicago Style (17a ed.)
Gourzoulidis, George, Vassiliki Chotzagiannoglou, Andriani Angelopoulou, Eleana Solakidou, y Charalampos Tzanetakos. "Cost-effectiveness Analysis of Liposomal Irinotecan in Combination with Oxaliplatin, 5-fluorouracil and Leucovorin (NALIRIFOX) for the First-line Treatment of Adult Patients with Metastatic Adenocarcinoma of the Pancreas in Greece." Expert Review of Pharmacoeconomics & Outcomes Research Aug. 2026: 1-10.
Cita MLA (9a ed.)
Gourzoulidis, George, et al. "Cost-effectiveness Analysis of Liposomal Irinotecan in Combination with Oxaliplatin, 5-fluorouracil and Leucovorin (NALIRIFOX) for the First-line Treatment of Adult Patients with Metastatic Adenocarcinoma of the Pancreas in Greece." Expert Review of Pharmacoeconomics & Outcomes Research, Aug. 2026, pp. 1-10.
Precaución: Estas citas no son 100% exactas.